Literature DB >> 27312001

Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom.

Keitaro Senoo1, Yoshimori An2, Hisashi Ogawa2, Deirdre A Lane1, Andreas Wolff3, Eduard Shantsila1, Masaharu Akao2, Gregory Y H Lip1,4.   

Abstract

BACKGROUND: Data on stroke, mortality and associated comorbidities in elderly patients with atrial fibrillation (AF) in Japan may differ from Western countries. There have been few systematic comparisons between stroke risk profiles and outcomes among community-based elderly (aged ≥75 years) patients with AF in Japan and the UK. OBJECTIVE AND METHODS: We compared clinical characteristics, stroke risk and outcomes among elderly patients with AF from the Fushimi AF Registry (Japan; N=1791) and the Darlington AF Registry (UK; N=1338).
RESULTS: The Fushimi cohort had a mean age 81.8 (standard deviation (SD) 5.3) years and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years (double), diabetes mellitus, previous thromboembolism (double), vascular disease, age 65-74 years and female gender) score 4.3 (1.4), whereas the Darlington cohort had a mean age 83.6 (5.7) years and CHA2DS2-VASc score 4.4 (1.4). Over a 12-month follow-up period, observed stroke and mortality rates in Fushimi were 3.4% (n=61) and 11.5% (n=206), while corresponding event rates in the Darlington cohort were 4.4% (n=59) and 14.1% (n=188), respectively. Appropriate use of oral anticoagulation (OAC, essentially a vitamin K antagonist) was <60% in both registries.On multivariable analysis, ethnicity (Japan vs UK) was neither associated with the risk of stroke (OR 0.92, 95% CI 0.63 to 1.36; p=0.69) nor death (OR 0.92, 95% CI 0.80 to 1.27; p=0.92). In a subgroup analysis of elderly patients not receiving OAC (n=1489), a history of stroke was associated with the risk of stroke (OR 2.42, 95% CI 1.39 to 4.12; p=0.002), but not ethnicity (OR 0.86, 95% CI 0.50 to 1.47; p=0.58).
CONCLUSIONS: Elderly (age ≥75 years) patients with AF in both Japan and the UK are at similarly high risk of stroke and death, with OAC still underused in both populations. Ethnicity was not independently associated with the risk of stroke, regardless of OAC use or non-use. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Stroke

Mesh:

Substances:

Year:  2016        PMID: 27312001     DOI: 10.1136/heartjnl-2016-309741

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial.

Authors:  Theresa M Lee; Noah M Ivers; Sacha Bhatia; Debra A Butt; Paul Dorian; Liisa Jaakkimainen; Kori Leblanc; Dan Legge; Dante Morra; Alissia Valentinis; Laura Wing; Jacqueline Young; Karen Tu
Journal:  Implement Sci       Date:  2016-12-03       Impact factor: 7.327

2.  Ethnicity and anticoagulation management of hospitalized patients with atrial fibrillation in northwest China.

Authors:  Xinchun Cheng; Xianhui Zhou; Shifei Song; Min Wu; Roza Baolatejiang; Yanmei Lu; Yaodong Li; Wenhui Zhang; Wenkui Lv; Yuanzheng Ye; Qina Zhou; Hongli Wang; Jianghua Zhang; Qiang Xing; Baopeng Tang
Journal:  Sci Rep       Date:  2017-04-10       Impact factor: 4.379

3.  Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.

Authors:  Brice Blum; Leah Wormack; Mason Holtel; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  BMC Womens Health       Date:  2019-01-16       Impact factor: 2.809

4.  Age-Related Clinical Outcomes of Patients with Non-Valvular Atrial Fibrillation: Insights from the COOL-AF Registry.

Authors:  Rungroj Krittayaphong; Thanita Boonyapiphat; Chaiyasith Wongvipaporn; Poom Sairat
Journal:  Clin Interv Aging       Date:  2021-04-28       Impact factor: 4.458

5.  Identifying risk patterns in older adults with atrial fibrillation by hierarchical cluster analysis: A retrospective approach based on the risk probability for clinical events.

Authors:  Shinya Suzuki; Takeshi Yamashita; Takayuki Otsuka; Takuto Arita; Naoharu Yagi; Mikio Kishi; Hiroaki Semba; Hiroto Kano; Shunsuke Matsuno; Yuko Kato; Tokuhisa Uejima; Yuji Oikawa; Minoru Matsuhama; Mitsuru Iida; Tatsuya Inoue; Junji Yajima
Journal:  Int J Cardiol Heart Vasc       Date:  2021-09-28

6.  Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry.

Authors:  Takeshi Yamashita; Shinya Suzuki; Hiroshi Inoue; Masaharu Akao; Hirotsugu Atarashi; Takanori Ikeda; Ken Okumura; Yukihiro Koretsune; Wataru Shimizu; Hiroyuki Tsutsui; Kazunori Toyoda; Atsushi Hirayama; Masahiro Yasaka; Takenori Yamaguchi; Satoshi Teramukai; Tetsuya Kimura; Jumpei Kaburagi; Atsushi Takita
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-03-02

7.  Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: A meta-analysis.

Authors:  Juan Xu; Yimeng Sun; Dandan Gong; Yu Fan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-01       Impact factor: 6.055

8.  Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry.

Authors:  Takeshi Yoshimoto; Kazunori Toyoda; Masafumi Ihara; Hiroshi Inoue; Takeshi Yamashita; Shinya Suzuki; Masaharu Akao; Hirotsugu Atarashi; Takanori Ikeda; Ken Okumura; Yukihiro Koretsune; Wataru Shimizu; Hiroyuki Tsutsui; Atsushi Hirayama; Masahiro Yasaka; Hirofumi Maruyama; Satoshi Teramukai; Tetsuya Kimura; Yoshiyuki Morishima; Atsushi Takita; Takenori Yamaguchi
Journal:  Stroke       Date:  2022-04-20       Impact factor: 10.170

9.  Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

Authors:  Jean-Pierre Bassand; Gabriele Accetta; Wael Al Mahmeed; Ramon Corbalan; John Eikelboom; David A Fitzmaurice; Keith A A Fox; Haiyan Gao; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Karen Pieper; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.